Photo: morningstar.com
Novo Nordisk Adjusts Earnings Forecast Amid Rising Competition for Ozempic and Wegovy
Novo Nordisk has revised its earnings forecast due to escalating competition and pricing pressure affecting sales of its popular drugs, Ozempic and Wegovy, in Denmark and beyond.
- Novo Nordisk has narrowed its earnings guidance, facing increased competition and pricing pressure from lower-cost versions of Ozempic and Wegovy in the U.S. market.
- Compounding pharmacies in the U.S. have been producing cheaper versions of Ozempic and Wegovy, a practice permitted by the U.S. Food & Drug Administration during supply shortages.
- Distribution of these lower-cost knockoff versions is anticipated to cease by the end of May, as authentic Ozempic and Wegovy supplies become available again.
Por Qué Es Relevante
This adjustment by Novo Nordisk reflects broader trends in the pharmaceutical industry, where competition from generics and pricing pressures can jeopardize profits. The implications extend to global markets, affecting drug affordability and patient access.